



Aligos Therapeutics Appoints David Perry as Vice President of Business Development

Oct 1, 2024

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately.

"We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline, including ALG-055009, which recently announced positive topline data."

"I am excited to join Aligos at this critical time in the Company's growth, given the significant potential of its clinical stage therapeutics," stated David Perry, Vice President, Business Development at Aligos. "I look forward to working with the team to strategically advance our drug candidates for patients searching for a better outcome."

Mr. Perry joins Aligos with more than 20 years of experience in the life sciences industry, leading corporate strategy, business development and execution, financings and investment management. Most recently, he served as Senior Director of Business Development at Sangamo Therapeutics, where he was responsible for the company's business strategy and partnering initiatives concerning the company's genomic medicine platform technologies. He led a pivotal transaction that resulted in Sangamo's most recent licensing deal with Genentech, the first transaction involving its blood brain barrier crossing AAV capsid delivery platform. Previously, Mr. Perry served as Senior Director and Head of Business Development at Apexigen Inc., a clinical-stage oncology therapeutics company. There he led collaboration and licensing deals as well as co-leading a strategic alternatives process that resulted in the acquisition by Pyxis Oncology.

His prior experiences include corporate development at Sumitomo Chemical where he led M&A for a North American subsidiary and the establishment of a corporate venturing unit that contributed to multiple early-stage investments. He started his career in healthcare investment banking at Asante Partners. Mr. Perry earned a B.S. in environmental engineering from Tufts University.

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including without limitation, statements regarding Aligos' financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos' clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos' capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos' Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2024 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics

Contact

Jordyn Tarazi

Vice President, Investor Relations & Corporate Communications

+1 (650) 910-0427

jtarazi@aligos.com

Media Contact

Inizio Evoke

Jake Robison

Vice President

Jake.Robison@inzioevoke.com